Rupsa guha biography of williams

Abstract

AliyaPulsed Electric Field (PEF) technology is an emerging strategy in the field of cancer treatment, offering a novel approach to ablation therapy that does not rely on thermal mechanisms. By employing a multi-stage experimental setup, including potato tuber, porcine liver, and murine breast cancer models, we explored the dose-response relationship on ablation and immune modulation by varying the pulse packets delivered from 20 to 100. The biologic response observed with 60 packets represented a minimum effective dose yielding reproducible ablation parameters, immune response, and efficacy which could be augmented with immune checkpoint blockade. This pre-clinical analysis provides a first step toward understanding the therapeutic index for PEF technology beyond ablation, a consideration that will require robust clinical validation in well-designed prospective studies.

Introduction

Modern treatments in solid tumor oncology have evolved to incorporate rational dose-response relationships such as dose-dense chemotherapy, hypofractionated radiotherapy (HFRT), and stereotactic body radiation therapy (SBRT) to improve patient tolerability while maintaining efficacy [1–3]. Many of these strategies were originally proposed in animal models and later validated through prospective clinical investigation. Like radiotherapy, a number of thermal ablative modalities have been studied with the hope of stimulating systemic immune-mediated or abscopal responses beyond focal tumor ablation [4], where the emphasis has shifted towards potential synergies with systemic treatments. It can be argued that ablation is not a binary event and may reflect dose-dependent parameters. In combination with systemic therapies, complex interdependencies may arise within the tumor microenvironment that rely on the mechanism of cell death and injury response.

A promising avenue in the evolution of ablation is the AliyaPulsed Electric Field (PEF) technology. Unlike traditional mo